Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/93411
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
Author: Olver, I.
Grimison, P.
Chatfield, M.
Stockler, M.
Toner, G.
Gebski, V.
Harrup, R.
Underhill, C.
Kichenadasse, G.
Singhal, N.
Davis, I.
Boland, A.
McDonald, A.
Thomson, D.
Citation: Supportive Care in Cancer, 2013; 21(6):1561-1568
Publisher: Springer Verlag
Issue Date: 2013
ISSN: 0941-4355
1433-7339
Statement of
Responsibility: 
I. N. Olver, P. Grimison, M. Chatfield, M. R. Stockler, G. C. Toner, V. Gebski, R. Harrup, C. Underhill, G. Kichenadasse, N. Singhal, I. D. Davis, A. Boland, A. McDonald, D. Thomson, for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Abstract: PURPOSE: The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy. METHODS: In a single-arm, open-label, multi-center, phase 2 trial, chemo-naive patients received aprepitant 125 mg PO (per oral) on day 1 and 80 mg PO on days 2 to 7, a 5HT3 receptor antagonist on days 1 to 5, and dexamethasone 8 mg on days 1 to 8. The primary endpoint was no emesis (vomiting or dry retching) during days 1 to 7 of cycle 1. RESULTS: Fifty patients were recruited. For cycle 1, proportions reporting no emesis on day 1, no emesis on days 1 to 7, no nausea on day 1, and no nausea on days 1 to 7 were 96, 82, 71, and 27%, respectively. The efficacy was maintained in all cycles with over 80% of patients reporting no emesis on any given day of any given cycle. Emesis was more common on days 4 to 7 (68% episodes) than on days 1 to 3 (32% episodes). Over any 24-h period, 49% of patients with emesis reported no more than two episodes, and 62% of patients with nausea reported intensity as 3 or less on a scale from 0 to 10. There were no unexpected or serious adverse events reported. CONCLUSION: Adding 7 days of aprepitant to a 5HT3 receptor antagonist and dexamethasone effectively controlled acute and delayed emesis with 5-day cisplatin regimens. Days of nausea were more common than days of vomiting.
Keywords: Aprepitant
Dexamethasone
5Hydroxytryptamine3 receptor antagonist
5-day cisplatin
Antiemetic
Germ cell tumors
Rights: © Springer-Verlag Berlin Heidelberg 2012
DOI: 10.1007/s00520-012-1696-0
Grant ID: NHMRC
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.